The Longevity Digest 02/24 - 03/02
I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.
Welcome to The Longevity Digest.
The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.
I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.
Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.
This Newsletter Is Sponsored By Casa de Sante.
Dr Onyx MD PhD’s Insights on this week’s episodes
Rewriting Metabolic Control: From Willpower Myths to Appetite Engineering
The obesity and metabolic story across these episodes moves decisively away from personal failure and toward “wiring problems” in appetite, hormones, and muscle.
On Health Longevity Secrets – “Why Am I Always Hungry?” with Jason Fung, MD, hunger is reframed as a thermostat problem, not a character flaw: insulin, cortisol, GLP‑1, and sympathetic tone set a body‑fat “setpoint” that then drives hunger, satiety, and energy expenditure. In practice, that means a chronically hungry patient is usually over‑signaled, not under‑disciplined. Dr. Fung’s focus on fasting insulin, ultra‑processed food removal, and social context turns obesity and type 2 diabetes into disorders of hyperinsulinemia and dysregulated hunger rather than failed willpower.
On The Second Opinion – “The Wegovy Pill”, Dr. Paul Kolodzik effectively shows what happens when you pharmacologically hijack that thermostat: oral semaglutide (Wegovy pill) is the same GLP‑1 molecule as the injections, delivering near‑comparable 13–16% weight loss—so long as patients can execute a very specific morning‑empty‑stomach protocol and clear classic GLP‑1 contraindications. The adherence risk is behavioral (daily ritual, GI tolerability), not just biochemical.
This Week in Cardiology (Feb 27, 2026) adds two crucial reality checks. First, even well‑counseled patients often reject statins when they see the absolute benefit; preference‑sensitive decisions do not always align with guideline logic. Second, newer oral GLP‑1s like orforglipron may outperform oral semaglutide on A1c and weight but at the cost of more GI discontinuations and heart‑rate signals—reminding us that “better numbers” can still fail in the real world if side‑effect friction is high.
Layered on top, The Human Upgrade – “The Secret to Staying DANGEROUS After 50” pushes the conversation from “lose weight” to “protect muscle and mitochondria.” Mitochondrial peptides (elamipretide, MOTS‑c), GH secretagogues (ipamorelin/CJC‑1295, tesamorelin), and myostatin‑targeting constructs are all framed as upstream tools to preserve power, lean mass, and endothelial health—especially in midlife patients, including those on GLP‑1s who are shedding both fat and muscle. The message is clear: you can pharmacologically drive weight loss, but if you ignore protein intake and resistance training, you are quietly engineering frailty.
Strategically, this cluster of episodes pushes clinicians and operators toward a new default:
Start with biology, not willpower. Make fasting insulin, hunger patterning (homeostatic vs hedonic vs conditioned), sleep, and meds that drive appetite (steroids, antipsychotics, beta‑blockers) part of the standard metabolic workup—not an afterthought.
Design for preference and friction. Expect that some patients will value fewer pills or needles over marginal efficacy gains, just as many still decline statins despite meaningful risk reduction.
Pair GLP‑1s with muscle protection by design, not as an optional add‑on. The peptide discussion on The Human Upgrade and the focus on protein plus resistance training across the Wegovy and GLP‑1 conversations converge on one point: sarcopenic weight loss is a strategic failure for longevity care.
This Newsletter Is Sponsored By Casa de Sante.
For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:
Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss
FODMAP Digestive Enzymes – improves absorption and reduces GI side effects
Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome
Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss
Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation
All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.
Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:
HydraLift Collagen Complex – firms and smooths for youthful elasticity
Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress
Needle-Free Wrinkle Smoother – softens fine lines without irritation
Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol
Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles
Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair
Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck
Even Tone Brightening Cream – evens discoloration for radiant, balanced skin
Programming the Signaling Environment: Light, Stress, and the Digital Mind
The second through‑line is that your environment—light, stress load, social and digital cues—acts like a multi‑channel prescription pad for your internal pharmacy. You are either writing good scripts or bad ones every day.
On Huberman Lab – “Essentials: Using Light to Optimize Health”, light is treated as a systemic drug. Morning and daytime short‑wavelength light to the eyes and skin is positioned as a lever for circadian timing, sex‑steroid tone, immune readiness, and even pain tolerance, while the same spectrum from 10 p.m. to 4 a.m. is a metabolic and mood toxin. Practical “light hygiene” emerges as: outdoor morning/daylight whenever possible, mid‑day UVB to skin a few times a week (avoiding sunburn and ocular exposure), and aggressively dim/red light in the evenings—especially for patients with sleep, mood, fertility, or pain complaints.
The Human Upgrade – “The Home Laser That Reverses Skin Age By 20 Years” zooms in on targeted 808‑nm photobiomodulation as a precision extension of that same logic. A diffused, retina‑safe, coherent 808‑nm home laser (e.g., LYMA) is described as driving dermal gene‑expression changes, including a six‑fold increase in SIRT1 and upregulation of type I collagen, without thermal injury. That positions non‑ablative NIR devices as a lower‑risk adjunct or alternative for skin aging, scar remodeling, and potentially deeper‑tissue support, provided claims stay within FDA‑cleared indications and protocols (3 minutes per area, daily, over 4–12 weeks) are standardized and photographed.
On The Human Upgrade – “A‑List Celebrities’ Anti‑Aging Hack to Look 30 at 50 (Drug‑free)”, telomere biology is brought down to earth: the safer play is not to chase pharmacologic telomerase activators with theoretical oncogenic risk, but to treat chronic stress as a telomere‑shortening toxin. Meditation, breathwork, circadian hygiene, and foundational lifestyle (no smoking, minimal ultra‑processed food, moderate exercise with small doses of high intensity, hormetic cold/heat) are framed as low‑risk ways to tune telomere maintenance and slow biological aging.
Huberman Lab – “Unlearn Negative Thoughts & Behavior Patterns” with Dr. Alok Kanojia extends that into the cognitive and relational domain. Distress intolerance, intolerance of uncertainty, and ego‑driven striving are presented as transdiagnostic drivers of modern psychopathology—amplified by high‑arousal, algorithmic feeds and even sycophantic AI/chatbot use. The tools are simple but potent: affect labeling, cultivating counterbalancing emotions, Shunya meditation, Yoga Nidra with a sankalpa, autonomic breathwork, and strict pre‑sleep digital hygiene.
Taken together with Dr. Fung’s emphasis on hedonic and conditioned hunger in “Why Am I Always Hungry?”, you get a unified picture: ultra‑processed food, blue‑light after dark, and doom‑scrolling are all versions of the same problem—chronic, mismatched signaling to systems that evolved for a very different environment.
For a longevity‑focused clinic or executive health program, the implication is operational, not philosophical:
Write “signal prescriptions” with the same seriousness as drug prescriptions. Morning light, mid‑day sun exposure, and evening light restrictions; daily 10‑minute stress‑reduction routines; and 60‑minute pre‑sleep device fasts should sit in the care plan as ordered interventions, not soft suggestions.
Treat home photobiomodulation as a procedural adjunct with QA. Define candidacy, standardize dosing and photography, and document outcomes so that 808‑nm devices sit alongside, not outside, your dermatologic and post‑procedural toolbox.
Embed mental skills for distress and uncertainty into care pathways. Brief, repeatable tools (2–3 minute “distress‑tolerance resets,” Yoga Nidra scripts, breathwork) can be taught in‑visit and reinforced digitally, giving patients levers they can actually pull when stress threatens sleep, diet, or adherence.
Longevity Moonshots vs. Public‑Health Ground Truth
The final theme is a widening gap between what is technically possible and what is operationally true in clinics and communities. The episodes juxtapose epigenetic reprogramming trials and AI‑designed drugs with measles outbreaks, vaccine gaps, and ambivalent patients who decline foundational therapies.
On The Human Upgrade – “Mexican Cartel Biohacking, Google Anti‑Aging Breakthrough, Measles Is Back, Age Reversal In 2026”, early human trials of partial epigenetic reprogramming (Yamanaka‑factor based, starting in the eye) and Isomorphic Labs’ closed AI platform for small‑molecule design are cast as near‑term reality. At the same time, the most actionable intervention is painfully basic: audit MMR coverage as measles resurges and shore up herd immunity before hospital capacity and vulnerable patients pay the price. This tension—moonshot biology, first‑tier public health infrastructure—mirrors a broader pattern in aging medicine, where only a small fraction of health spending goes to prevention while the vast majority is consumed by high‑tech interventions for late‑stage disease.
This Week in Cardiology underscores how this plays out in cardiovascular care. The push toward pulsed‑field ablation and percutaneous LAA closure runs into sobering data: severe spontaneous echo contrast (atrial “smoke”) and non‑paroxysmal AF predict worse thromboembolic outcomes after Watchman implantation, arguing for continued anticoagulation in high‑risk atrial myopathy until randomized trials like LAAOS‑4 report. Meanwhile, PFA has workflow advantages but no clear outcome superiority, along with unresolved safety and cost concerns. Overlay that with patients who decline statins even at high ASCVD risk and you have a system chasing capital‑intensive innovation while under‑delivering on shared decision‑making and foundational risk reduction.
In parallel, The Human Upgrade peptide episode – “The Secret to Staying DANGEROUS After 50” and the “Mexican cartel biohacking” thread highlight a different risk: injectable “wellness” products and research‑use‑only peptides are now global commodities, increasingly used in unregulated settings. Clinically sophisticated peptides (elamipretide, MOTS‑c, Klotho constructs, follistatin‑based myostatin inhibitors) sit in the same practical marketplace as gray‑market stacks purchased with no oversight—raising clear safety, sourcing, and equity issues.
Across these conversations, a consistent strategic pattern emerges:
Reinforce low‑glamour, high‑yield interventions first. Systematically auditing MMR status, optimizing light, sleep, diet, and physical strength, and getting blood pressure and LDL under control will likely deliver more near‑term healthspan than any early‑phase rejuvenation trial.
Treat new tech as an adjunct, not a substitute, until outcomes and selection rules are clear. That applies to epigenetic reprogramming, PFA, LAA closure in high‑SEC atrial myopathy, advanced GLP‑1 formulations, and investigational peptides.
Build governance and communication infrastructure now. Clinics that will win in longevity over the next decade are already developing:
Clear protocols for vetting off‑label or investigational therapies (GLP‑1s in non‑obesity indications, peptides, home lasers).
EHR‑driven population tools (vaccine and metabolic risk registries, flags for severe SEC on TEE, structured documentation of patient risk‑benefit thresholds).
Language that aligns high‑stakes decisions with patient values—e.g., “Do Not Attempt CPR” framing and transparent discussions of absolute risk reductions for statins and GLP‑1s.
In short, these episodes collectively argue for a longevity strategy that is both more radical and more conservative: radical in how aggressively it reprograms signaling environments (hunger, light, stress, digital load) and targets upstream biology, and conservative in demanding rigorous selection, monitoring, and public‑health basics before declaring any new tool a panacea.
This weeks episodes:
1. Health Longevity Secrets
Why Am I Always Hungy? | Jason Fung MD
Published: 2026-02-24
URL: Listen Here
Summary
Dr. Jason Fung argues that hunger biology and hormonal regulation—not willpower or calorie math—drive weight gain, introducing a ‘body fat thermostat’ framework and three types of hunger (homeostatic, hedonic, conditioned). He outlines practical strategies—fasting, reducing ultra-processed foods, and leveraging social supports—and notes that successful pharmacotherapies like GLP-1 RAs work by suppressing hunger, underscoring the primacy of hormonal targets in modern obesity care.
Key Takeaways
Calories-in/calories-out is a true but clinically unhelpful tautology; body weight is primarily regulated by hormones and hunger biology rather than willpower alone.
A homeostatic ‘body fat thermostat’ adjusts weight via hormones (e.g., insulin, cortisol push setpoint up; GLP-1, glucagon signaling, sympathetic tone, and gastric stretch push it down) by modulating hunger, satiety, and metabolic rate.
Hunger has three drivers: homeostatic (physiologic), hedonic (reward/emotion), and conditioned (habit/social cues). Ultra-processed foods amplify hedonic/conditioned hunger and blunt satiety.
Interventions that lower insulin and hunger—fasting, carbohydrate reduction, GLP-1 receptor agonists—outperform simple calorie cutting; sleep, medications (e.g., steroids, beta-blockers, antipsychotics), and social environment meaningfully affect appetite and weight.
Practical ‘golden rules’: minimize ultra-processed foods, use fasting strategically, and cultivate supportive social habits/community to sustain behavior change.
Clinical Insight
Reframe obesity and type 2 diabetes as disorders of hyperinsulinemia and dysregulated hunger; targeting hormonal drivers and appetite regulation is more effective and sustainable than prescribing calorie restriction alone.
Actionable Takeaway
Add a fasting insulin to standard metabolic labs and, if elevated, initiate a 12–16-hour daily fasting window and eliminate ultra-processed foods to lower insulin and hunger; reassess weight, appetite, and metabolic markers in 8–12 weeks.
2. The Human Upgrade: Biohacking for Longevity & Performance
The Home Laser That Reverses Skin Age By 20 Years : 1421
Published: 2026-02-24
URL: Listen Here
Summary
This episode details a portable 808-nm near-infrared laser that maintains coherence and depth via a patented diffused lens, enabling retina-safe home use and deep photobiomodulation without tissue damage. The discussion contrasts it with LED and ablative lasers, cites a human dermal gene-expression study showing a six-fold SIRT1 increase, and outlines practical applications from skin rejuvenation, scars, and pigmentation to joint pain and circulation—relevant to longevity-focused and dermatologic practice.
Key Takeaways
A home-use 808-nm near-infrared “cold” laser (LYMA) with patented diffused-lens technology delivers coherent, polarized light safely and deeply (~9 cm) without heat or tissue damage; typical dose is ~12 J in 3 minutes per area.
Unlike LED or ablative/fractional lasers, this modality avoids injury yet increases type I collagen and remodels deeper tissues (including supporting muscle), improving skin laxity/lift, scars, thread veins, and pigmentation; hairline use and pigment prevention were discussed.
A human dermal gene-expression study (Aesthetic Surgery Journal) found 45 genes activated with the LYMA laser, including a six-fold increase in SIRT1; the LED comparator activated only one gene, suggesting superior epigenetic/longevity signaling with the laser.
Practical uses highlighted: facial/jowl tightening, post-surgical recovery (e.g., C-section, knee replacement), joint pain mitigation, travel-related circulation, thread veins, pigmentation control, and exploratory neurocognitive/sexual-health applications—while adhering to the device’s FDA-cleared skin indication.
Safety is engineered via a retina-safe diffused lens (40+ patents); coherence is preserved while the beam is dispersed. Overuse is unlikely (battery-limited). Suggested regimens: 3 minutes daily per area for 4–12 weeks (longer for hypertrophic/keloid scars); twice daily for some scars.
Clinical Insight
Non-ablative 808-nm photobiomodulation with a diffused, coherent, polarized laser can drive robust dermal gene-expression changes (notably six-fold SIRT1 upregulation) and type I collagen synthesis without thermal injury—positioning it as a lower-risk adjunct or alternative to ablative lasers/LED for skin rejuvenation, scar remodeling, and potentially deeper-tissue support.
Actionable Takeaway
For appropriate patients, trial targeted 808-nm PBM (e.g., LYMA) at 3 minutes per treatment area daily for 4–12 weeks (longer for hypertrophic/keloid scars), with standardized before/after photography; use as an adjunct for post-procedural healing or dermal laxity while limiting claims to FDA-cleared skin indications.
3. The Second Opinion Podcast with Dr. Paul Kolodzik
EP 110 The Wegovy Pill: Transformative Impacts on Health and Weight Management with Dr. Paul Kolodzik
Published: 2026-02-26
URL: Listen Here
Summary
This episode reviews the newly available Wegovy pill (oral semaglutide): how to take it, expected efficacy versus injections, key contraindications, and practical conversion from injectables. It also discusses evolving and off-label applications (e.g., alcohol-use reduction, cardioprotection), improving affordability via discount programs, and the need for protein intake and resistance training to preserve lean mass.
Key Takeaways
The Wegovy pill is oral semaglutide (same molecule as Wegovy injection/Ozempic) and must be taken in the morning with 4 oz of water, with no food or drink for 30 minutes; expected weight loss is roughly 13–16%, slightly less than with injections.
Discussed FDA-approved uses include diabetes and chronic weight management (BMI ≥30, or ≥27 with a comorbidity); additional potential uses mentioned (some off-label/evolving) include alcohol-use reduction, dementia, reduced risk of recurrent cardiac events, and osteoarthritis knee pain.
Key contraindications/cautions highlighted: personal/family history of medullary thyroid carcinoma or MEN2, gastroparesis or significant GI motility disorders/GERD, prior pancreatitis, and kidney disease; rodent data underlie the thyroid warnings.
Oral dosing tiers described as 1.5 → 3 → 7 → 14 mg daily (higher than injections due to lower bioavailability). When converting from higher-dose injections (1.7–2.4 mg weekly), many patients can start at a mid-range oral dose if prior GI tolerance was good.
Access and cost are improving via manufacturer discounts (e.g., ~$149 for first 2 months, then ~$249/month at higher doses for some patients), while lifestyle measures—adequate protein and resistance training—are essential to limit lean-mass loss on therapy.
Clinical Insight
Daily oral semaglutide (Wegovy pill) is a viable alternative to injections for chronic weight management with near-comparable efficacy when taken correctly, but it requires careful screening for GLP-1 contraindications and deliberate muscle-preserving lifestyle support.
Actionable Takeaway
When initiating the Wegovy pill, counsel patients to take it first thing in the morning with 4 oz water and avoid all intake for 30 minutes, and screen for MTC/MEN2, gastroparesis/severe GERD, prior pancreatitis, and renal disease before prescribing.
4. Huberman Lab
Essentials: Using Light to Optimize Health
Published: 2026-02-26
URL: Listen Here
Summary
This episode distills how different wavelengths and timings of light drive systemic biology—from circadian and endocrine signaling (melatonin, sex steroids) to analgesia, immune priming, skin/hair turnover, and retinal function. It translates mechanistic and emerging human data into practical ‘light hygiene’ protocols (daytime sunlight, evening dim/red light, cautious red/NIR use in older adults) relevant to sleep, mood, pain, fertility, and aging. Limitations: some findings are preclinical or from early human studies; individual risk (ocular disease, skin cancer) warrants clinician guidance.
Key Takeaways
Daytime short-wavelength light (UVB/blue) to the eyes and skin powerfully modulates melatonin, circadian timing, endocrine function, immune readiness, and pain tolerance; conversely, short-wavelength light at night suppresses melatonin and can worsen mood—avoid 10 p.m.–4 a.m. exposure.
UVB exposure to skin (not eyes) can acutely raise testosterone and estrogen, increase mating drive (mice) and alter related psychology (humans), and in females enhance follicle maturation; a practical protocol discussed is 20–30 minutes of sunlight to as much skin as safely possible, 2–3 times per week.
Bright light to the eyes activates melanopsin pathways that increase endogenous opioids in the periaqueductal gray, elevating pain tolerance; windows and most windshields block UVB, and blue-blocking lenses should be reserved for evening/night, not morning/day.
Red/near-infrared light (~670/790 nm) penetrates deeper tissues, improving mitochondrial ATP and reducing ROS; brief early-day exposures (2–3 minutes) improved aging retinal function and reduced drusen in human studies, and red/NIR supports skin healing and scar/pigment reduction.
Clinical light hygiene: seek outdoor morning/daylight year-round (consider bright light devices in winter/SAD), keep evening lights dim and low in the visual field, favor dim red light for necessary night work, and use caution in patients with ocular disease or high skin-cancer risk.
Clinical Insight
Light is a potent, accessible physiologic modulator—proper timing and wavelength-specific exposure can beneficially influence sleep, mood, pain, hormones, immune function, and even age-related visual decline, while nighttime short-wavelength exposure can be deleterious.
Actionable Takeaway
Advise patients to obtain 20–30 minutes of midday outdoor sunlight to the skin 2–3 times per week (avoiding sunburn and ocular injury) to support sex-hormone balance, pain tolerance, and immune readiness, and to minimize bright/short-wavelength light after dusk.
5. The Human Upgrade: Biohacking for Longevity & Performance
The Secret to Staying DANGEROUS After 50 : 1422
Published: 2026-02-26
URL: Listen Here
Summary
This episode reviews practical peptide therapeutics for longevity and performance—covering delivery advances, PK-driven dosing, and key agents for mitochondria (elamipretide, MOTS-c), GH axis (tesamorelin, ipamorelin/CJC-1295), myostatin inhibition (follistatin-based), and endothelial/renal support (Klotho). Much of the discussion involves investigational products and anecdotal outcomes; clinicians should rely on evidence-based indications, monitor safety (especially renal), and use quality-assured sources.
Key Takeaways
Peptides are short chains of amino acids that act as signaling molecules; delivery innovations (e.g., insulin-style peptide pens now, microneedle patches emerging) and attention to pharmacokinetics (PK curves) meaningfully improve efficacy and adherence.
Mitochondrial-targeted peptides: elamipretide (formerly SS-31) stabilizes cardiolipin to support foundational mitochondrial function (often felt as subtle, system-wide benefits), while MOTS-c tends to produce a more noticeable, rapid boost in cellular energy/ATP; some users stack MOTS-c with NAD+ support.
Growth hormone axis support can often be achieved with secretagogues instead of exogenous GH: tesamorelin (FDA-approved for HIV-associated visceral adiposity) and the ipamorelin + CJC-1295 stack are commonly used; MK-677 (ibutamoren) raises GH/IGF-1 but can increase appetite and stress hormones, warranting caution.
Two investigational, long–half-life, albumin-binding constructs discussed: a follistatin-based agent (FLGR242) designed to reduce myostatin and favor lean mass gain/fat loss (not FDA-approved), and low-dose Klotho peptide intended to support endothelial, renal, and cognitive function and libido; careful dosing and renal safety monitoring are emphasized.
Clinical practice pearls: blend peptides by indication when needed (real-world stability appears acceptable over typical storage intervals), prioritize one therapeutic goal at a time, align dosing with circadian/PK considerations, and use high-quality sourcing given regulatory variability around “research-use” peptides.
Clinical Insight
Targeting aging biology upstream—particularly mitochondrial integrity (e.g., elamipretide) and endothelial/renal health (e.g., microdosed Klotho)—may yield broad functional benefits in midlife and beyond, while growth hormone secretagogues often provide a safer, titratable alternative to exogenous GH; however, many peptide interventions remain investigational and require careful sourcing, dosing, and monitoring.
Actionable Takeaway
In midlife patients with low IGF-1 or sarcopenia—especially those on GLP-1 agents—prioritize a lean-mass preservation plan: supervised resistance training and adequate protein (≈1.2–1.6 g/kg/day), and where legally/ethically appropriate consider a monitored trial of GH secretagogues (e.g., ipamorelin + CJC-1295 at bedtime or tesamorelin per labeling in HIV lipodystrophy) with baseline and follow-up IGF-1/glucose assessments.
6. The Human Upgrade: Biohacking for Longevity & Performance
Mexican Cartel Biohacking, Google Anti-Aging Breakthrough, Measles Is Back, Age Reversal In 2026 : 1423
Published: 2026-02-27
URL: Listen Here
Summary
This episode spotlights the tension between cutting-edge longevity advances—human trials of epigenetic age reversal and closed AI-driven drug design—and basic public health gaps such as measles’ return. Clinically, the most actionable move is to shore up MMR coverage while tracking forthcoming rejuvenation data and policy shifts that will determine access and cost of emerging therapies.
Key Takeaways
Early human trials of partial epigenetic reprogramming (Yamanaka factor–based, starting in the eye) are underway, with initial efficacy and safety readouts potentially by 2026.
Google DeepMind’s spinoff Isomorphic Labs has built a closed, end-to-end AI platform for small-molecule design that may accelerate discovery for aging-related targets but could limit access and affordability due to its proprietary model.
Biohacking and injectable ‘wellness’ products have diffused globally—even into unregulated settings—highlighting the need for rigorous sourcing, sterility, and clinical oversight.
Measles cases are resurging in the U.S.; maintaining high MMR vaccination coverage is a high-yield safeguard for patients and for preserving healthcare system capacity.
Federal policy signals on drug pricing, Medicaid, fentanyl, and telehealth will shape access and costs for GLP-1s, lipid-lowering biologics, and future longevity therapies; clinicians should monitor these shifts.
Clinical Insight
Reinforcing foundational public health measures—specifically verifying and updating MMR vaccination—has immediate, high-impact clinical value amid measles resurgence and protects limited healthcare capacity, even as advanced rejuvenation and AI-designed therapies rapidly evolve.
Actionable Takeaway
Audit patient immunization records now: use your EHR to flag patients without documented MMR immunity (two doses or positive serology for those born in 1957 or later, per risk-based guidance) and proactively vaccinate or order serologic testing where appropriate, following CDC recommendations and contraindication screening.
7. This Week in Cardiology
Feb 27 2026 This Week in Cardiology
Published: 2026-02-27
URL: Listen Here
Summary
This episode highlights how patient preferences (e.g., for statins) often diverge from guideline expectations even after robust education, reviews emerging GLP-1 data favoring oral orforglipron over oral semaglutide, and cautions that atrial myopathy markers (SEC) predict poor outcomes after LAA closure. It also tempers enthusiasm for pulsed-field ablation by emphasizing unresolved safety, value, and knowledge-erosion concerns while advocating clearer DNACPR terminology in end-of-life discussions.
Key Takeaways
Advance-care planning: CPR should be framed as a specific intervention within broader ‘resuscitation’ efforts; adopting “Do Not Attempt CPR (DNACPR)” language may preserve appropriate peri-arrest treatments and improve acceptance of orders that limit chest compressions and intubation.
Statin preferences: In a JAMA Internal Medicine survey using the ‘smallest worthwhile difference’ framework, many informed adults declined statins even at moderate–high 10-year ASCVD risk; the median benefit patients require to accept therapy exceeded statins’ expected absolute risk reduction.
GLP-1 updates: In ACHIEVE-3 (Lancet), oral orforglipron achieved greater A1c and weight reductions than oral semaglutide but with more GI discontinuations and slightly higher heart-rate increases; an ongoing Seminal AF trial will test whether semaglutide reduces atrial fibrillation events.
LAA closure caution: A Japanese multicenter registry found severe spontaneous echo contrast (SEC) is linked to higher ischemic events and markedly higher device-related thrombus after Watchman implantation, especially with non-paroxysmal AF—underscoring that atrial myopathy biology, not just appendage mechanics, drives stroke risk.
PFA ablation: Despite workflow advantages, current data do not show clear superiority over thermal ablation; concerns include hemolysis/AKI, rare late malignant arrhythmias/possible coronary spasm, substantially higher cost, and potential erosion of mechanistic EP thinking.
Clinical Insight
Severe left-atrial ‘smoke’ (spontaneous echo contrast), particularly in non-paroxysmal AF, signals advanced atrial myopathy and portends high device-related thrombus and thromboembolism after percutaneous LAA closure—arguing for continued anticoagulation and stricter patient selection until randomized data (e.g., LAAOS-4) clarify benefits of adding closure to OAC.
Actionable Takeaway
Before referring for LAA closure, document SEC severity on TEE and AF type; in patients with severe SEC and non-paroxysmal AF, favor ongoing oral anticoagulation over percutaneous appendage closure and reassess when LAAOS-4 results are available.
8. The Human Upgrade: Biohacking for Longevity & Performance
A-List Celebrities’ Anti-Aging Hack to Look 30 At 50 (Drug-free) : 1424
Published: 2026-03-01
URL: Listen Here
Summary
This episode argues that targeting cellular aging via telomere maintenance—particularly by reducing chronic stress—may be safer and more feasible than pharmacologically activating telomerase. It highlights meditation and breathwork as accessible, evidence‑supported methods to lower cortisol, increase telomerase activity, and potentially slow biological aging, alongside foundational lifestyle measures. Evidence cited includes small, controlled and cross‑sectional studies; clinical application should recognize these limitations and focus on low‑risk, behavior‑based interventions.
Key Takeaways
Cellular aging is closely linked to telomere shortening; lobsters resist this by sustaining telomerase activity across tissues throughout life.
Indiscriminate pharmacologic activation of telomerase may pose oncogenic risk, so safer, non-drug strategies are emphasized.
Foundational behaviors (no smoking/vaping, minimal processed foods, consistent moderate exercise with brief high‑intensity sessions, hormetic cold/heat exposure, circadian optimization with morning light and dark bedrooms) support telomere maintenance.
Chronic psychosocial stress elevates cortisol and is associated with shorter telomeres (e.g., in caregivers), effectively accelerating biological aging.
Meditation and paced breathing can reduce stress physiology and have been associated with increased telomerase activity and longer telomeres; a consistent 10-minute daily practice is recommended.
Clinical Insight
Stress-reduction interventions—particularly structured meditation and breathwork—are supported by peer‑reviewed evidence showing increases in telomerase activity and associations with longer telomeres, making them practical, low‑risk adjuncts to healthy aging care plans while avoiding the potential cancer risks of direct telomerase activation.
Actionable Takeaway
Prescribe a daily 10‑minute stress‑reduction routine (e.g., mindfulness or box breathing: inhale 4 seconds, hold 4, exhale 4, hold 4) at a consistent time each day for at least 8 weeks, paired with circadian hygiene (morning outdoor light, blackout sleep environment), and reassess perceived stress, sleep quality, and adherence at follow‑up.
9. Huberman Lab
Unlearn Negative Thoughts & Behaviors Patterns | Dr. Alok Kanojia
Published: 2026-03-02
URL: Listen Here
Summary
This episode integrates Eastern contemplative psychology with Western clinical practice to show how to unlearn maladaptive thoughts and behaviors by targeting core, transdiagnostic processes—especially distress intolerance and ego-identified striving. Practical tools include affect labeling, cultivating counterbalancing emotions, Shunya meditation, Yoga Nidra with sankalpa, autonomic breathwork, and digital hygiene (timing and dose of social media/AI). The discussion also addresses relationships (ambiguity and signaling), pornography’s evolving risks, and why focusing on intrinsic drives—not ego comparisons—improves mental health and functioning.
Key Takeaways
Distress tolerance and intolerance of uncertainty are key transdiagnostic drivers of psychopathology that are worsening in the internet era; effective skills include affect labeling (putting words to feelings), cultivating additional/adjacent emotions, and treating emotions as information and motivation rather than directives.
A practical roadmap for authentic goals requires distinguishing ego-driven, comparison-based desires (conditioned by senses and social media) from intrinsic drives; practices like Shunya (void) meditation help access a self-state beyond ego to guide decisions.
Emotion regulation is not willpower suppression: labeling emotions recruits language networks and downshifts limbic activation; embarrassment is a prosocial corrective signal after boundary violations; cultivate the ‘opposite’ emotion when overly positive (e.g., anxiety for due diligence) or negative (e.g., gratitude for perspective).
Digital hygiene is clinical: emotionally arousing, algorithmically curated feeds exhaust cognition, erode sleep (especially near bedtime), and can distort reality testing; excessive, customized AI/chatbot use may sycophantically amplify users’ biases and, in rare cases, precipitate psychosis-like states—screen for timing, dose, and purpose of use.
Evidence-informed tools: Yoga Nidra with a sankalpa (resolve) leverages a hypnoyogic state to rewrite deep beliefs; alternate-nostril/cardiac-coherence breathing improves autonomic balance; meditation reduces default mode network activity; somatosensory ‘body-rotation’ awareness can aid chronic pain; in relationships, allow ambiguity in early flirting, create shared emotional experiences, and prioritize signaling and purpose over ‘looks-maxing’; attend to pornography’s shift toward parasocial engagement and rising young-male sexual dysfunction.
Clinical Insight
Target transdiagnostic processes (distress intolerance, intolerance of uncertainty, rumination/perfectionism) with brief, skills-based interventions—especially affect labeling, deliberate cultivation of counterbalancing emotions, and reframing emotion as information—rather than relying on willpower or behavior-only prescriptions; concurrently screen for high-arousal digital habits (pre-sleep social media, AI/chatbot reliance, pornography) that perpetuate these processes.
Actionable Takeaway
Teach a 2–3 minute ‘distress-tolerance reset’ patients can use in-session and at home: (1) pause and name the dominant emotion out loud or in writing; (2) add one deliberate, adjacent emotion (e.g., gratitude, curiosity, or prudent anxiety) to broaden appraisal; (3) ask, “What is this emotion telling me to do?” and select a small, value-aligned action; prescribe a 60-minute pre-sleep device fast to protect sleep and reduce arousal carryover.
Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:
Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website
From Insights to Action
Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:
Personalized Medical AI Chatbot
Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.
Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.
It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.
👉 Deploy your Medical AI Chatbot today and take control of your health narrative
Premium Longevity Program
For people who know their most valuable asset is their health.
This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.
👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.